Article
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.
Antimicrobial agents and chemotherapy - 1 Mar 2008
de Requena Daniel Gonzalez, Bonora Stefano, Calcagno Andrea, D'Avolio Antonio, Siccardi Marco, Fontana Silvia, Milia Maria Grazia, Sciandra Mauro, Garazzino Silvia, Di Garbo Antonio, Baietto Lorena, Trentini Laura, Di Perri Giovanni
Abstract excerpt
The virological response (VR) to a tipranavir-ritonavir (TPV-RTV)-based regimen had been shown to be associated with a number of mutations in the protease gene, the use of enfuvirtide (T20), and the TPV phenotypic inhibitory quotient (IQ). The role of the TPV genotypic IQ (gIQ) has not yet been fully investigated. The aim of our study was to evaluate the relationship between the TPV gIQ and the VR at 48 weeks to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.